One of the biggest assets in the acquisition is Global Blood Therapeutics’ Oxbryta, a sickle cell disease treatment that the FDA approved in November 2019. Last year, the company raked in $195 million in net sales for the pills, according to the press release.
Sickle cell disease, a lifelong blood disorder, affects about 100,000 Americans and is most common among populations of African, South American, Middle Eastern and South Asian descent, according to CDC estimates.
Both companies’ boards of directors approved the all-cash transaction, but no final acquisition date was provided.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
